Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

KRAS Inhibitor

Geo Regions

KRAS Inhibitor

PF-07985045 is an investigational compound. Its safety and efficacy have not been established

Share to an HCP

Overview + Rationale

RATIONALE FOR CANCER TARGET:

  • KRAS encodes a GTPase protein that regulates cellular growth by linking growth factor receptors to intracellular signaling pathways1
  • Mutations in KRAS can lead to uncontrolled cell growth and are found in 20-30% of human solid tumors1-3

 

OVERVIEW:

  • PF-07985405 is an oral inhibitor of the KRAS pathway4

 

 

Stage of Development

Other
KRAS-Mutated Advanced Solid Tumors
Phase 1 Monotherapy and Combination
This information is current as of March 28th 2025.

FDA=Food and Drug Administration; GTPase=guanosine triphosphatase; KRAS=Kirsten rat sarcoma viral oncogene homologue

REFERENCES: 1. Shen H, Lundy J, Strickland AH, Harris M, Swan M, Desmond C, Jenkins BJ, Croagh D. KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation? Cells. 2022 Oct 10;11(19):3175. doi: 10.3390/cells11193175. PMID: 36231137; PMCID: PMC9562007; 2. Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, Zhang W, Qin JJ. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022 Aug 4;21(1):159. doi: 10.1186/s12943-022-01629-2. PMID: 35922812; PMCID: PMC9351107; 3. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. doi: 10.1038/s41392-021-00780-4. PMID: 34776511; PMCID: PMC8591115; 4. Clinicaltrials.gov https://clinicaltrials.gov/study/NCT06447662 Accessed March 04, 2025.